These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28044946)

  • 21. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
    Mattes JA
    J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports.
    Koyuncu A; Çelebi F; Ertekin E; Kahn DA
    J Psychiatr Pract; 2015 May; 21(3):225-31. PubMed ID: 25955266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Autism and attention deficit hyperactivity disorder: pharmacological intervention].
    Fernández-Jaén A; Martín Fernández-Mayoralas D; Fernández-Perrone AL; Calleja-Pérez B; Muñoz-Jareño N; López-Arribas S
    Rev Neurol; 2013 Sep; 57 Suppl 1():S205-10. PubMed ID: 23897149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment and treatment of attention-deficit/hyperactivity disorder: part 2.
    French WP
    Pediatr Ann; 2015 Apr; 44(4):160-8. PubMed ID: 25875981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coming into focus. Pharmacologic treatment for ADHD.
    McDonnell MA; Moffett C
    Adv NPs PAs; 2010 Dec; 1(4):16-22; quiz 23. PubMed ID: 21319448
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
    Hodgkins P; Sasané R; Meijer WM
    Clin Ther; 2011 Feb; 33(2):188-203. PubMed ID: 21497704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL; Chia S; Shang CY; Gau SS
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Stimulant and non-stimulant medication in current and future therapy for ADHD].
    Franke AG; Konrad A; Lieb K; Huss M
    Fortschr Neurol Psychiatr; 2012 Mar; 80(3):130-40. PubMed ID: 21611939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F; Connor DF; Newcorn JH
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
    Spiller HA; Hays HL; Aleguas A
    CNS Drugs; 2013 Jul; 27(7):531-43. PubMed ID: 23757186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
    Roman MW
    Issues Ment Health Nurs; 2010 Aug; 31(8):548-9. PubMed ID: 20624025
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.